Soligenix, Inc. (SNGX)
NASDAQ$2.3
Market Cap
$5.77M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
847 of 924
Rank in Industry
481 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
SNGX Insider Trading Activity
SNGX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Soligenix, Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of …
Insider Activity of Soligenix, Inc.
Over the last 12 months, insiders at Soligenix, Inc. have bought $0 and sold $0 worth of Soligenix, Inc. stock.
On average, over the past 5 years, insiders at Soligenix, Inc. have bought $17,899 and sold $2,701 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $8,866 was made by SCHABER CHRISTOPHER J (CHAIRMAN, CEO AND PRESIDENT) on 2022‑05‑18.
List of Insider Buy and Sell Transactions, Soligenix, Inc.
| 2022-05-18 | SCHABER CHRISTOPHER J | CHAIRMAN, CEO AND PRESIDENT | 20,000 0.0466% | $0.44 | $8,866 | +23.81% | ||
| 2022-05-18 | Straube Richard | SENIOR VICE PRESIDENT AND CMO | 8,000 0.021% | $0.50 | $4,000 | +23.81% | ||
| 2021-12-17 | SCHABER CHRISTOPHER J | CHAIRMAN, CEO AND PRESIDENT | 7,000 <0.0001% | $0.74 | $5,179 | -13.05% | ||
| 2021-12-15 | Guarino Jonathan L. | Senior Vice President and CFO | 1,000 <0.0001% | $0.70 | $700 | -10.86% | ||
| 2021-12-14 | SCHABER CHRISTOPHER J | Chairman, CEO and President | 10,000 0.0001% | $0.73 | $7,269 | -7.05% | ||
| 2021-12-14 | Guarino Jonathan L. | Senior Vice President and CFO | 10,000 0.0001% | $0.71 | $7,119 | -7.05% | ||
| 2021-05-14 | Sale | ZELDIS JEROME B | director | 3,000 <0.0001% | $0.90 | $2,701 | +1.43% | |
| 2021-05-14 | ZELDIS JEROME B | director | 3,000 <0.0001% | $0.89 | $2,664 | +1.43% | ||
| 2019-11-19 | SCHABER CHRISTOPHER J | Chairman, CEO and President | 10,770 0.0544% | $0.93 | $10,016 | +92.63% | ||
| 2019-11-19 | ZELDIS JEROME B | director | 2,000 0.0101% | $0.93 | $1,850 | +92.63% | ||
| 2019-09-23 | Parks Diane L. | director | 14,940 0.0003% | $0.93 | $13,870 | +95.33% | ||
| 2019-09-19 | ZELDIS JEROME B | director | 4,000 <0.0001% | $0.94 | $3,740 | +93.21% | ||
| 2019-04-22 | SCHABER CHRISTOPHER J | Chairman, CEO and President | 5,000 0.0001% | $0.72 | $3,577 | +47.89% | ||
| 2019-04-22 | ZELDIS JEROME B | director | 10,000 0.0002% | $0.73 | $7,274 | +47.89% | ||
| 2018-10-18 | SCHABER CHRISTOPHER J | Chairman, CEO and President | 8,700 0.0002% | $1.17 | $10,177 | -22.88% | ||
| 2018-10-17 | Pearson Mark E. | director | 170,000 0.0046% | $1.16 | $197,200 | -13.90% | ||
| 2018-08-22 | SCHABER CHRISTOPHER J | Chairman, CEO and President | 3,530 <0.0001% | $1.42 | $5,012 | -30.71% | ||
| 2017-11-29 | Sale | Essetifin SPA | 16,416 0.0012% | $2.12 | $34,802 | -19.31% | ||
| 2017-11-29 | Essetifin SPA | 293,510 0.0223% | $2.12 | $622,241 | -19.31% | |||
| 2017-05-08 | Sale | KIRK RANDAL J | 10 percent owner | 11,576 0.0009% | $2.54 | $29,403 | -16.86% |
Total: 56
Insider Historical Profitability
62.23%
| CAVAZZA PAOLO | 10 percent owner | 54227816 2160.9012% | $124.72M | 3 | 0 | |
| CAVAZZA CLAUDIO | 10 percent owner | 54227816 2160.9012% | $124.72M | 3 | 0 | |
| BAM Management LLC | 10 percent owner | 21766092 867.3478% | $50.06M | 1 | 1 | |
| Pearson Mark E. | director | 2500000 99.6214% | $5.75M | 1 | 0 | |
| KANZER STEVE H | director | 1282203 51.094% | $2.95M | 1 | 0 |
Historical Insider Profitability vs. Competitors
$18,881,323 | 88 | -48.96% | $4.47M | |
$296,936 | 37 | -18.12% | $4M | |
$523,320 | 24 | 94.37% | $7.01M | |
$31,129 | 22 | -11.96% | $6.19M | |
$51,865 | 17 | -38.70% | $6.16M |
SNGX Institutional Investors: Active Positions
| Increased Positions | 7 | +116.67% | 11,648 | +17.62% |
| Decreased Positions | 2 | -33.33% | 47,192 | -71.39% |
| New Positions | 4 | New | 326 | New |
| Sold Out Positions | 2 | Sold Out | 47,192 | Sold Out |
| Total Postitions | 11 | +83.33% | 30,557 | -53.77% |
SNGX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Geode Capital Management, Llc | $60.00 | 0.87% | 26,094 | +7,729 | +42.09% | 2024-12-31 |
| Morgan Stanley | $9.00 | 0.13% | 3,816 | +3,592 | +1,603.57% | 2024-12-31 |
| Ubs Group Ag | $1.00 | 0.01% | 313 | +313 | New | 2024-12-31 |
| Plante Moran Financial Advisors, Llc | $1.00 | 0.01% | 300 | 0 | 0% | 2024-12-31 |
| Bank Of America Corp /De/ | $0 | <0.01% | 20 | +<1 | +5.26% | 2024-12-31 |
| Jones Financial Companies Lllp | $0 | 0% | 10 | +10 | New | 2024-12-31 |
| Sbi Securities Co., Ltd. | $0 | 0% | 2 | +2 | New | 2024-12-31 |
| Cwm, Llc | $0 | 0% | 1 | +<1 | New | 2024-12-31 |
| Albion Financial Group /Ut | $0 | 0% | 1 | 0 | 0% | 2024-12-31 |
| Stephens Inc /Ar/ | $0 | 0% | 0 | -46,262 | Sold Out | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.